Indivior Pharmaceuticals, Inc 6-K, filed Dec 5, 2023
Indivior Pharmaceuticals, Inc. (INDV)
6-K
2023-12-05
For: 2023-12-05
View Original
Added on
April 10, 2026
About this 6-K
Indivior Pharmaceuticals, Inc filed this 6-K on December 5, 2023.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Date: December 05, 2023
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ☐
|
|
EXHIBIT INDEX
|
Exhibit
No.
|
Description
of Exhibit
|
|
99.1
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
Indivior PLC
|
|
Date: December 05,
2023
|
/s/
Kathryn Hudson
|
|
|
Name:
Kathryn Hudson
|
|
|
Title:
Company Secretary
|
Exhibit
99.1
FOR IMMEDIATE RELEASE
Indivior Prevails in Striking Representative Claims from UK
Shareholder Action
Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC
(LSE/NASDAQ: INDV), a leading addiction treatment
company, announced that the High Court of Justice of England and
Wales has issued a judgment striking out representative claims
by Wirral Council as administering
authority of Merseyside Pension fund ("Wirral")
against Indivior under the Financial Services and Markets Act 2000
("FSMA"). Wirral's suit was the first attempt by claimants to
use representative proceedings for securities claims brought under
Sections 90, 90A, and Schedule 10 of the FSMA. The proposed
representative proceedings, if allowed, would permit a
representative acting on behalf of unnamed claimants to attempt to
prove a violation of law without proof of damages, in contrast to
ordinary multi-party proceedings, which require proof of liability
and damages for each claimant.
In September 2022, Wirral had filed a representative claim
generally asserting that Indivior violated the FSMA by making
misleading or dishonest statements regarding an alleged fraudulent
scheme to switch the market for its
SUBOXONE® branded products in published
information relating to securities. A similar claim was filed
against Reckitt Benckiser.
After hearing two days of argument in November 2023, the High Court
on December 5 issued a judgment granting Indivior's and Reckitt
Benckiser's applications to strike out the representative
proceedings. The Court specifically found that it "would be
unfair and unjust, and contrary to the overriding objective, to
allow the Representative Proceedings to oust the jurisdiction of
the Court to case manage the claims from the start." The Court's
judgment may be found here.
Wirral and other claimants separately had filed a multi-party
action generally alleging the same claims, and levied similar
allegations against Reckitt Benckiser Group PLC ("Reckitt
Benckiser") in separate actions. Pursuant to the Court's judgment,
the claim against Indivior may only proceed in those multi-party
proceedings brought by the claimants named in those proceedings.
Wirral may seek permission to appeal the Court's
judgment.
About Indivior
Indivior is a global pharmaceutical company working to help change
patients' lives by developing medicines to treat addiction and
serious mental illnesses. Our vision is that all patients around
the world will have access to evidence-based treatment for the
chronic conditions and co-occurring disorders of substance use
disorder (SUD). Indivior is dedicated to transforming SUD from a
global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a
pipeline of product candidates designed to both expand on its
heritage in this category and potentially address other chronic
conditions and co-occurring disorders of SUD, including alcohol use
disorder and cannabis use disorder. Headquartered in the
United States in Richmond, VA, Indivior employs more
than 1,000 individuals globally and its portfolio of products is
available in 37 countries worldwide.
Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by
visiting www.linkedin.com/company/indivior.
This release is being made by Kathryn Hudson, Company Secretary
Indivior PLC.
Media
Contacts:
US Media:
Cassie France-Kelly
Vice President, Communications
Indivior PLC
Tel: 804-724-0327
UK Media:
Teneo
Tel: +44 207-353-4200
Investors
and Analysts:
Jason Thompson
Vice President, Investor Relations
Indivior PLC
Tel: 804-402-7123
Tim Owens
Director, Investor Relations
Indivior PLC
Tel: 804-263-3978
-ends-